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Available online 7 December 2015Several reports have shown antimicrobial and anticancer activities of mucous glycoproteins extracted from the
giant African snail Achatina fulica. Anticancer properties of the snail mucous peptides remain incompletely re-
vealed. The aim of this studywas to predict anticancer peptides from A. fulicamucus. Two of HPLC-separatedmu-
cous fractions (F2 and F5) showed in vitro cytotoxicity against the breast cancer cell line (MCF-7) and normal
epithelium cell line (Vero). According to the mass spectrometric analysis, 404 and 424 peptides from the F2
and F5 fractions were identiﬁed. Our comprehensive bioinformatics workﬂow predicted 16 putative cationic
and amphipathic anticancer peptides with diverse structures from these two peptidome data. These peptides
would be promising molecules for new anti-breast cancer drug development.
© 2015 The Authors. Published by Elsevier B.V. on behalf of the Research Network of Computational and








Breast cancer is oneof themost commondiseases inwomen globally
[1]. Several factors make women at high risk of the breast cancer [2].
Early detection and the use of radiation therapy, surgery, and chemo-
therapeutic drugs including selective estrogen receptor modulators
(SERMs) and aromatase inhibitors can reduce invasive breast cancer.
However, the patients remain traumatized by the unfavorable side ef-
fects [3,4]. The search for target-speciﬁc and less side-effect cancer ther-
apy is still undergoing.
Anticancer peptides have been proved to be effective small mole-
cules (b50 amino acids) that can act speciﬁcally against cancerous
cells by either membranolytic mechanism or disruption of mitochon-
dria [5]. The net negative charge of the cancer membrane is an impor-
tant factor for peptides' selectivity and toxicity [6], as compared to the
typically zwitterionic property of non-cancerous eukaryotic mem-
branes. Amphiphilicity levels and hydrophobic arc size allow penetra-
tion of these peptides through the cancerous cell membranes and lead
to destabilization of the membrane integrity [7,8]. For example,
pleurocidin-like peptides (NRCs) identiﬁed from ﬁsh could kill breast
cancer cells and humanmammary epithelial cells by causingmembrane, Faculty of Science, Kasetsart
kok 10900, Thailand. Tel.: +66
).
on behalf of the ResearchNetwork ofdamage with subtle harm to human ﬁbroblasts [9]. These cell-
penetrating peptides could be used as cancer-speciﬁc drug delivery.
For example, the non-speciﬁc cell-penetrating anticancer peptide
buforin IIb was modiﬁed to enhance the cancer speciﬁcity with no ef-
fects on normal cells [10]. This cancer-speciﬁc peptide derivative was
successfully used to deliver apoptosis-induced antibody into the cancer
cells. Distinctively, a peptide SA12 could induce apoptosis on SKBr-3
breast cancer cells by the mitochondrial pathway [11]. Taken together,
these physicochemical properties and experimentally validated infor-
mation were used to develop bioinformatic programs for anticancer
peptide prediction and design. AntiCP predicts anticancer peptides by
using amino acid composition and binary proﬁles to develop support
vector machine models (SVM) [12]. Another SVM-based program,
ACPP, particularly screens for anticancer peptides that contain apoptotic
domain [13]. In this regard, these prediction tools will assist high-
throughput screening for anticancer peptides from complex
peptidomes of an array of natural products.
Giant African snails (Achatina fulica) are invasive animals that seri-
ously cause damages to agricultural and ornamental plants worldwide.
Only one antimicrobial peptide, namely Mytimacin-AF, was identiﬁed
from the mucus of A. fulica [14]. Mytimacin-AF (9.7 kDa) was a novel
cysteine-rich peptide that could inhibit the growth of both fungi and
bacteria with little hemolytic effect on human red blood cells. However,
we hypothesized that the anticancer peptides from the mucus of
A. fulicamay not be completely revealed. Thus, this study aimed to pre-
dict putative anticancer peptides from the most effective HPLC-Computational and Structural Biotechnology. This is an open access article under theCCBY
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using mass spectrometric and bioinformatic analysis methods. Our re-
sults provide alternative high-throughput screening methods to identi-
fy potential anticancer peptides from nearly a thousand peptides within
the snail mucus for further validation.
2. Experimental procedure
2.1. Cell culture
The breast cancer cell line MCF-7 and the kidney epithelial cell line
Vero used in this study were kindly provided by the Department of Bio-
chemistry, Faculty of Medicine, Chiangmai University, Thailand and the
Genome Institute, National Center for Genetic Engineering and Biotech-
nology (BIOTEC), Thailand. The cells were cultured and passaged in
Dulbecco's Modiﬁcation of Eagle's Medium (DMEM, Gibco-RBL, Life
Technologies, NY) supplemented with 10% Fetal Bovine Serum (FBS,
Hyclone, Thermo Fisher Scientiﬁc Inc., USA), 1% Penicillin–Streptomycin
(PAA, Laboratories GmbH, Austria) and 1% Amphotericin B (PAA, Labo-
ratories GmbH, Austria). The cells were maintained at 37 °C in 95% rel-
ative humidiﬁed atmosphere containing 5% CO2. Cell growth was
measured under a light microscope and 80% conﬂuence of the cells
was used in all experiments.
2.2. Separation of A. fulica mucus by HPLC
The snail mucus samples were collected from adult A. fulica by inter-
mittent irritation in an ultrasonicating bath at 30 °C sporadically. The
crude mucous samples were separated by ZORBAX 300SB-
4.6 × 150mm C18 column, 5 μm, (Agilent, Palo Alto, CA) with Agilent®
1200 system using methanol–water (50:50) with 0.1% triﬂuoroacetic
acid (adjusted from [15]) as mobile phase and the ﬂow rate was
0.30 ml/min. Numbers of the HPLC peaks were used to determined
numbers of the fractions. Six HPLC-separated mucous fractions were
collected manually and named as F1, F2, F3, F4, F5 and F6 fractions. All
HPLC fractions and the crude mucus were concentrated by freeze-
drying at−100 °C and kept at−20 °C until use.
2.3. Determination of cytotoxicity of the mucous fractions by MTT assay
Cell viability count was performed using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazoliumbromide (MTT) assay [16]. Cellswere seed-
ed at 2 × 104 cells per well (200 μl/well) in 96-well tissue culture plates
and allowed cells to adhere for 24 h at 37 °C in the CO2 incubator. The
culture medium was then replaced with 200 μl/well of the fresh medi-
um for the control group and 200 μl/well of the fresh medium contain-
ing the same concentration (1000 μg/ml) of the crude mucus or the six
HPLC-separated fractions. After 72 h incubation, 50 μl/well of tetrazoli-
um bromide salt solution (2 mg/ml of stock in phosphate buffered sa-
line, PBS) was added into 150 μl of the cell suspension. Four hours
before completion, the reaction mixture was carefully taken out and
200 μl/well of dimethyl sulfoxide or DMSO (Sigma, USA) was added to
each well before the addition of 25 μl/well of Sorensen's glycine buffer
(Research Organics, USA). The optical densities (OD) were measured
at 570 nmusingmicroplate reader (Tecan Sunrise, Switzerland). Finally,
the highest effective anti-breast cancer fraction with the lowest per-
centage of cell viability was then selected for further analysis.
Cytotoxicity of the mucous fractions against the MCF-7 and Vero
cells was compared by slightly modiﬁed the above-described method
due to the limited quantity of the fractions. The cells were seeded at
4 × 103 cells per well in 96-well tissue culture plates and allowed cells
to adhere for 24 h at 37 °C in the CO2 incubator. The culture medium
was then replaced with 100 μl/well of the fresh medium for the control
group and 100 μl/well of the fresh medium containing three concentra-
tions (1, 10 and 100 μg/ml) of the crudemucus, the F2, and F5 fractions.
After 24 h incubation, 25 μl/well of tetrazolium bromide salt solution(5 mg/ml of stock in PBS) was added to the cell suspension. Four
hours before completion, the reaction mixture was carefully taken out,
and 100 μl/well of DMSO was added to each well. The optical densities
were measured at 570 nm.
2.4. Statistical analysis of the MTT assay
The resultswere presented asmean± sem(standard error ofmean)
ormean± sd (standard deviation). The parameters were analyzedwith
one-way analysis of variance (One-way ANOVA) followed by Sidak's
multiple comparisons test. Statistical analysis was conducted with
Graphpad Prism version 6.0 for Windows (Graphpad software, San
Diego, California, USA). Signiﬁcant levels were considered at p b 0.05
and highly signiﬁcant level at p b 0.01 comparing with control group.
2.5. Mass spectrometric analysis of the selected cytotoxic fractions
2.5.1. Sample fractionation
Individual selected fractionswere fractionated based on theirmolec-
ular size usingMacrosep® 3 K, 10 K and 50 K Omega centrifugal devices
(Pall Life Sciences, USA) into four sub-fractions: lower than 3 kDa, be-
tween 3 and 10 kDa, between 10 and 50 kDa, and larger than 50 kDa
sub-fractions. These sub-fractions were mixed well with two volumes
of cold acetone and incubated overnight at−20 °C. The mixture was
centrifuged at 10,000 ×g for 15min, and the supernatantwas discarded.
The pellet was freeze-dried and stored at−80 °C before use.
2.5.2. Determination of protein/peptide concentration by lowry method
The pellets were resuspended in 0.15% Sodium Deoxycholic acid
(DOC) or 0.5% SDS and determined protein concentration by Lowry
method [17]. The absorbance at 750 nm (OD750) was measured, and
the protein concentrationwas calculated using the standard curve, plot-
ted between OD750 on Y-axis and BSA concentration (μg/ml) on X-axis.
2.5.3. In-solution digestion
Each protein sub-fractionswere hydrolyzed by trypsin at an enzyme
to the protein ratio of 1:50 at 37 °C for 24 h, except the lower than 3 kDa
sub-fraction. The peptides were dried by vacuum centrifuge and kept at
−80 °C for further mass spectrometric analysis.
2.5.4. HCTultra LC–MS analysis of the peptidomes
Peptide solutions were analyzed using an HCTultra PTM Discovery
System (Bruker Daltonics Ltd., U.K.) coupled to anUltiMate 3000 LC Sys-
tem (Dionex Ltd., U.K.). Peptides were separated on a nanocolumn
(PepSwift monolithic column 100 μm i.d. × 50 mm). Eluent A was
0.1% formic acid, and eluent B was 80% acetonitrile in water containing
0.1% formic acid. Peptide separationwas achievedwith a linear gradient
from 10% to 70% B for 13 min at a ﬂow rate of 300 nl/min, including a
regeneration step at 90% B and an equilibration step at 10% B, one run
took 20 min. Peptide fragment mass spectra were acquired in data-
dependent AutoMS (2) mode with a scan range of 300–1500m/z, 3 av-
erages, and up to 5 precursor ions selected from the MS scan 50–
3000m/z.
2.5.5. Identiﬁcation of peptide sequences
The MS/MS data from LC–MS were submitted to database search
using theMascot software (Matrix Science, London, U.K., [18]). The pep-
tide sequence data was searched against the NCBI database for protein
identiﬁcation. Database interrogation was; taxonomy (other meta-
zoans); enzyme (trypsin); variable modiﬁcations (carbamidomethyl,
oxidation of methionine residues); mass values (monoisotopic); pro-
tein mass (unrestricted); peptide mass tolerance (1 Da); fragment
mass tolerance (±0.4 Da), peptide charge state (1+, 2+ and 3+),
maxmissed cleavages (1) and instrument= ESI-TRAP. Proteins consid-
ered as identiﬁed proteins had at least one peptides with an individual
Mascot score corresponding to p b 0.05. The resultant peptides with
Fig. 1.Workﬂow for bioinformatic prediction of putative anticancer, cytotoxic andmembrane-penetrating peptides (labeled with numbers 1, 2 and 3) obtained from peptidomic analysis
of A. fulicamucous fractions. Details were described in the text. CancerPPD (yellow box) was a database of anticancer peptides. ACPP, AntiCP, ToxinPred and CellPPD were the bioinfor-
matics prediction programs (blue boxes).
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signiﬁcance.
2.6. Bioinformatic prediction of anticancer peptides
The identiﬁed peptides from the fractions F2 and F5were then blast-
ed against a database of anticancer peptides (cancerPPD, [19]). These
peptides were screened for putative anticancer peptides by using con-
sensus prediction. Each peptide was submitted for the prediction of
two programs; ACPP [13] and AntiCP [12] for anticancer peptide predic-
tion based on amino acid composition, conserved features and
physicochemical properties. The hydrophobicity, hydrophilicity,Fig. 2.HPLC chromatogram shows retention times (minutes) of the six separated fractions
of the A. fulicamucus. The signal according to the diode array detector (DAD) is represent-
ed in milli-arbitary unit (mAU). The fractions were scanned at different ultraviolet wave-
lengths; 210 (pink), 220 (green), 230 (purple), 250 (red), 280 (brown green) and 290
(blue) nm.amphiphaticity and hydrophathicity scores were computed by AntiCP
and their means were statistically compared between the anticancer
and non-anticancer peptides by using an R package for independent
two sample t-test. Peptides positively predicted by both programs
were considered putative anticancer peptides. These peptides were
checked for toxicity by submission to ToxinPred for the prediction of
toxic peptides [20]. The predicted anticancer peptides were subjected
to CellPPD for prediction of cell penetrating properties [21]. These pep-
tides were classiﬁed into putative membrane-penetrating and non-
membrane-penetrating anticancer peptides (Fig. 1). If the number of
predicted anticancer peptides was very high, the cutoff score (from
0.5–1.0) was then applied to narrow the list down to a short list of
those with the high prediction scores. Structures of these putative anti-
cancer peptides were then modeled by the PEP-FOLD program version
1.5 [22]. Structural similarity was used to classify these predicted pep-
tide structures.3. Results and discussion
The A. fulicamucus was successfully collected by intermittent irrita-
tion and separated into six fractions by the C18-reverse phaseHPLC sys-
tem using methanol–water mobile phase. All six fractions were
manually collected and named as F1, F2, F3, F4, F5 and F6 fractions as
shown in Fig. 2. The fraction was scanned between 210 to 290 nm
which was a suitable range for peptide bond and aromatic amino acid
absorptions. The sample showed the highest signal when scanning at
220 nm, but revealed two distinguished peaks at the absorbance of
210, 230, 280 and 290 nm. Thus, these two peaks were collected in
the F3 and F4 fractions. The lowest signal peak was collected in the F2
fraction. Other three moderate signal peaks were collected in the F1,
F5 and F6 fractions.
Fig. 3. Percentages of theMCF-7 cell viability after 72 h treatmentwith A. fulica crudemucus and sixHPLC-separated fractions (F1, F2, F3, F4, F5 and F6) at the concentration of 1000 μg/ml.
The cell viability was measured by the MTT assay. Control was the untreated cells. Error bars represented the SEM, * and ** represented levels of signiﬁcance at p b 0.05 and p b 0.01.
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Cytotoxicity of the A. fulica crude mucus and six HPLC-separated
fractions (F1, F2, F3, F4, F5 and F6) on the MCF-7 cells were evaluated
by the MTT assay to measure cytotoxic effect on cell viability. Results
showed that fractions F1, F3, F4 and F6 did not signiﬁcantly induce cell
death (p N 0.05) comparing to the control group. The treatments of
these four fractions resulted in more than 85% of the viable cells. Oppo-
sitely, the crude mucus, fractions F2 and F5 signiﬁcantly had cytotoxic
effects to the MCF-7 cells (p b 0.05) comparing to the control group.
The F2 fraction showed the highest cytotoxic effect (50.03±3.38% of vi-
able cells) followed by crude mucus and the F5 fraction (80.91 ± 1.38
and 83.61 ± 2.26%, respectively) (Fig. 3).
Cytotoxicity against theMCF-7 and Vero cells was further compared
by varying the concentration of the crudemucus, the F2 and F5 fractions
to 1, 10 and 100 μg/ml. Results in Fig. 4 showed that the increasedFig. 4. Percentages of the Vero andMCF-7 cell viabilities after treatmentwith A. fulica crudemuc
was measured by the MTT assay. Control was the untreated cells. Error bars represented the S
signiﬁcance of p b 0.05. a, b, c, d, e and f: signiﬁcant difference between concentrations of the
g represented the signiﬁcant difference (p b 0.05) of the F2 fraction from the crude mucus andconcentration of crude mucus and the F2 fraction signiﬁcantly reduced
the viability of both cell types to 72–84% (p b 0.05). The F5 fraction at
100 μg/ml signiﬁcantly decreased the viability for both Vero and MCF7
cells but showed no different reduction at 1 and 10 μg/ml. The crude
mucus and these two fractions signiﬁcantly suppressed cell viability of
the Vero cells more than those of the MCF-7 cells (p b 0.05), except
the crudemucus at 100 μg/ml. The Vero cells were insigniﬁcantly affect-
ed by these three fractions at 100 μg/ml (p b 0.05), whereas the viability
of theMCF-7 cells were signiﬁcantly interfered by the crude mucus and
the F5 fractionmore than the F2. Although this experimentwas not con-
ducted at the concentration of 1000 μg/ml as described in the previous
section (Fig. 3) due to limited amount of the HPLC-separated fractions.
The percentages of cell viability from these two independent experi-
ments was unable to compare. However, the authors observed similar
pattern of the cell viability reduction between the crude mucus and
the F5 fraction. For the F2 fraction, the cytotoxic activity couldus and the F2 and F5 fractions at the concentration of 1, 10 and 100 μg/ml. The cell viability
D, * represented statistical difference between the viability of Vero and MCF-7 cells at the
crude mucus (a and b), the F2 (c and d) and F5 (e and f) fractions, respectively, p b 0.05.
the F5 fraction at 100 μg/ml.
Table 1
Details of putative anticancer peptides predicted from the F2 and F5 fractions of the A. fulicamucus by using four bioinformatics programs. Each fraction consisted of four sub-fractions: b3
kDa, 3–10 kDa, 10–50 kDa and N50 kDa. Predictive scores and amino acid sequence for each peptidewere also shown. These peptideswere structurally classiﬁed into ﬁve groups including
random coiled, a single helix, helix-consisted loop, β-sheet-consisted loop and short peptide. The SVM scores above the threshold of 0.90 are highlighted in red. The 16 signiﬁcantly pu-
tative anticancer peptides are showed in bold amino acid sequences.
ID Fraction Subfraction Amino acid sequence No of residues Programs Prediction scores Structural type
ACPP AntiCP CellPPD ToxinPred ACPP AntiCP CellPPD ToxinPred
0 F2 < 3kDa DTPRCCR 7 + + - + 0.70 1.24 -0.23 0.46 Short peptide
1 GGPIAAPEASK 11 + + - - 0.94 0.39 -0.38 -1.25 Random coiled
2 LGGIVVVVVSRR 12 + + - 0.62 0.53 -0.62 -1.10 Random coiled
3 GLAWGALLYLGAALADALGK 20 + + - - 0.83 0.54 -0.22 -0.92 Single helix
4 GIGSAAGAAVSLVYMLPK 18 + + - - 0.70 0.85 -0.32 -1.79 Single helix
5 NAIATTTQK 9 + + - - 0.88 0.50 -0.19 -0.70 Beta–sheet 
consisted loop
6 GIKINPGAFIQTISVIKVR 19 + + - - 0.78 0.19 -0.21 -0.99 Beta–sheet 
consisted loop
7 HNGCGSNGSTK 11 + + - - 0.66 0.59 -0.53 -0.83 Beta–sheet 
consisted loop
8 VKHLIGNF 8 + + - - 0.75 0.55 -0.28 -0.93 Short peptide
9 GGAMIMK 7 + + - - 0.61 0.38 -0.25 -0.72 Short peptide
10 VVPVCTK 7 + + - - 0.52 0.41 -0.26 -1.28 Short peptide
11 F2 3–10 kDa GGPIAAPEASK 11 + + - - 0.88 0.39 -0.38 -1.25 Random coiled
12 NAIATTTQK 9 + + - - 0.78 0.50 -0.19 -0.70 Random coiled
13 CVGLGGRGC 9 + + - - 0.72 0.93 -0.58 -0.62 Random coiled
14 GLAWGALLYLGAALADALGK 20 + + - - 0.83 0.54 -0.22 -0.92 Single helix
15 GIGSAAGAAVSLVYMLPK 18 + + - - 0.70 0.85 -0.32 -1.79 Single helix
16 MGIPRLGLVGIMGIPRLGLVGIQCK 25 + + - - 0.53 0.80 -0.34 -1.50 Helix–consisted 
loop
17 VKHLIGNF 8 + + - - 0.51 0.55 -0.28 -0.93 Short peptide
18 F2 10–50 kDa KLERAAGSK 9 + + + - 0.64 0.04 0.06 -1.01 Helix–consisted 
loop
19 GYAAGIK 7 + + - - 0.88 1.62 -0.24 -1.07 Short peptide
20 HANGGVLK 8 + + - - 0.58 1.16 -0.27 -1.08 Short peptide
21 F2 > 50 kDa GYAAGNK 7 + + - - 0.90 1.18 -0.24 -1.00 Short peptide
22 AAAIHVSK 8 + + - - 0.50 0.73 -0.24 -1.25 Short peptide
23 F5 < 3 kDa HALLIIFNASKK 12 + + - - 0.94 0.93 -0.34 -1.07 Random coiled
24 VCKALIPGLIPLSFGHGLEPK 21 + + - - 0.71 0.92 -0.29 -0.90 Random coiled
25 HLIKAKGSD 9 + + + - 0.78 0.82 0.17 -0.41 Random coiled
26 RNAGLAKLGSSLLGAAKSLMGK 22 + + - - 0.86 0.97 -0.20 -0.45 Single helix
27 IVASTMKIIK 10 + + - - 0.81 0.06 -0.32 -0.60 Single helix
28 LAVVGILGLGLLASIAALMRMISYK 25 + + - - 0.91 0.42 -0.43 -1.75 Helix–consisted 
loop
29 GGGTMGNAGGVGAAK 15 + + - - 0.77 0.83 -0.60 -0.62 Beta–sheet 
consisted loop
30 HAILLITKGIFK 12 + + - - 0.88 1.60 -0.11 -1.83 Beta–sheet 
Consisted loop
31 AGWRHAGS 8 + + - - 0.65 1.02 -0.24 -0.73 Short peptide
32 HKGCAMTA 8 + + - - 0.77 1.05 -0.26 -1.01 Short peptide
33 AGAGMHE 7 + + - - 0.69 0.32 -0.29 -0.64 Short peptide
34 F5 3–10 kDa VKGAPVKTK 9 + + - - 0.95 0.55 -0.17 -1.02 Random coiled
35 FSKGISKTGPK 11 + + - - 0.87 0.11 -0.18 -1.10 Random coiled
36 AKATKPDAK 9 + + + - 0.56 0.11 0.14 -0.32 Random coiled
37 VAGAVTSAK 9 + + - - 0.52 0.52 -0.62 -0.73 Random coiled
38 HSIKNFYLIAKPATKNGR 18 + + + - 0.66 0.06 0.02 -1.40 Helix–consisted 
loop
39 RGFNVIIK 8 + + - - 0.65 0.76 -0.25 -0.75 Short peptide
40 GCGNS 5 + + - - 0.56 1.15 -0.27 -0.66 Short peptide
41 F5 > 50 kDa YGGKFVAIK 9 + + - - 0.70 1.84 -0.18 -0.88 Random coiled
42 GNIAILKIMVK 11 + + + - 0.62 0.82 0.02 -1.24 Single helix
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hypothesis that peptides or proteins within the F2 and F5 fractions
could have different cytotoxic mechanisms against the cells. Modiﬁca-
tion of these peptides or proteins could enhance speciﬁcity to the
MCF-7 cells. Thus, the F2 and F5 fractions were selected for peptidomic
analysis.
3.2. Peptidomic identiﬁcation of the selected mucous fractions
The fractions F2 and F5 showed in vitro inhibitive effects on the
MCF-7 and Vero cells. These two fractions were then further separated
bymolecular masses into four sub-fractions: lesser than 3 kDa, between
3 kDa and 10 kDa, between 10 kDa and 50 kDa and larger than 50 kDa.
While the b3 kDa sub-fraction was directly subjected to the LC–MS/MS
analysis, the other three sub-fractions were tryptic digested in solution
prior mass spectrometric analysis. The MASCOT search of the results
against the NCBI database did not give signiﬁcant matched proteins, de-
spite 424 and 404 peptides were detected. Limited genomic and prote-
omic information of gastropods in the NCBI database caused this
unsuccessful protein identiﬁcation. If the database did not contain the
unknown peptides, it should at least ﬁnd the closest homologue. ThisFig. 5. Physicochemical properties of the putative anticancer peptides compared with the non-a
philicity (B), amphiphaticity (C) and hydrophathicity (D) scores of these peptides were comput
dots. The uppermost and lowermost ends represented maximum and minimum scores. The mﬁnding was similar to an annotation of a non-model gastropod Nerita
melanotragus transcriptome that only 15–18% of the contigs were
assigned with a putative function [23]. However, amino acid sequences
of these peptideswere further analyzed by peptidomics. Themajority of
these peptides (82–84%) were less than 10 kDa. These peptides were
blasted against the anticancer peptide database CancerPPD [19] to ﬁnd
similarities to any known anticancer peptides, but no signiﬁcant hits
were found.
Four bioinformatic programs; ACPP, AntiCP, CellPPD and ToxinPred,
were then used to predict putative anticancer peptides from the mass
spectrometric-detected peptides using our designed workﬂow in
Fig. 1. Forty-three putative anticancer peptides were ﬁrstly predicted
from the F2 and F5 fractions by both ACPP and AntiCP (Table 1) with
the positive prediction scores.
Of these 43 peptides, 23 (5.4%) peptides were from the F2 fraction
and 20 (4.9%) peptides were from the F5 fractions. The majority of the
putative anticancer peptides of the F2 and F5 fractions were less than
10 kDa with the range of sizes between 5 to 25 amino acids. Analysis
of physicochemical properties of the 43 putative anticancer peptides
by AntiCP showed a higher average score of hydrophobicity (p b 0.01)
and a lower average score of hydrophilicity (p b 0.01) in compared tonticancer peptides from fractions F2 and F5 of A. fulicamucus. Hydrophobicity (A), hydro-
ed by AntiCP. The boxplots were drawn by R program. The scores were shown in the black
iddle line indicated means and the two paralleled lines showed standard deviations.
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fractions (Fig. 5A and B). These putative cationic anticancer peptides re-
vealed a greater score of hydropathicity (p b 0.01) meaning that they
were more hydrophobic (Fig. 5D). Positive scores of amphipathicity
were averagely similar to the non-anticancer peptides (Fig. 5C). This
amphiphatic property indicated the ability of these peptides to bind
and penetrate the breast cancer cell membrane [7,8]. However, this
property was not clearly separated between the two groups in this
study.
Five of these peptides from both F2 and F5 fractions had cell pene-
trating ability as predicted by CellPPD and only one peptide from the
F2 fraction was toxigenic as predicted by ToxinPred. The CellPPD and
ToxinPred programs helped predicting speciﬁc characteristics of these
peptides. The results could partially explain the cytotoxic mechanisms
of the F2 and F5 fractions against the Vero and MCF-7 cells. More com-
plicated situations could be that different peptides worked in combina-
tion or the cytotoxicity was also concentration-dependent. The
predictions could select candidate peptides for further experimental
validations.
Structures of these 43 peptides were simple and could be classiﬁed
into ﬁve structural categories: random coiled, a single helix, helix-
consisted loop, β-sheet-consisted loop and short peptide (Fig. 6). The
short putative anticancer peptides (less than 9 amino acid residues)
were predominantly observed in the F2 fraction,whereas the F5 fraction
contained more of the random coiled peptides. Similar observation [24]
was shown in the classiﬁcation of antimicrobial peptides from the ADP
database that the majority of the antimicrobial peptides had no known
structure (40%). Notably, most of the known structures of these pep-
tides were β-sheet structure with disulﬁde bonds and helical structure.
As the predictions relied on the support-vector-machine (SVM)
score for conﬁdent determination of the anticancer peptides by
ACPP and AntiCP programs, the threshold of 0.9 was optimally set
for the putative anticancer peptide candidates. Applying this strin-
gent criterion narrowed the result down to 16 signiﬁcantly putative
cationic anticancer peptides (Table 1 and Fig. 7). Four short-length
(No 0, DTPRCCR; No 19, GYAAGIK; No 20, HANGGVLK and No 21,Fig. 6. Structural predictions of the putative anticancer peptides obtained from the F2 and F5 fr
b3 kDa, 3–10 kDa, 10–50 kDa and N50 kDa. The peptide contents of these sub-fractions were an
the b3 kDa sub-fraction. Putative anticancer peptides and their structures were predicted by bio
siﬁed into ﬁve categories: random coiled, a single helix, helix-consisted loop, β-sheet-consisted
the top half, while those of the F5 fraction were shown on the bottom half. The asterisks indicaGYAAGNK) and two random-coiled (No 1, GGPIAAPEASK and No
13, CVGLGGRGC) peptides were from the F2 fraction, while ten pep-
tides were from the F5 fraction which contained one single helix (No
26, RNAGLAKLGSSLLGAAKSLMGK), one helix-consisted loop (No 28,
LAVVGILGLGLLASIAALMRMISYK), one β-sheet-consisted loop (No
30, HAILLITKGIFK), four random-coiled (No 23, HALLIIFNASKK; No
24, VCKALIPGLIPLSFGHGLEPK; No 34, VKGAPVKTK and No 41,
YGGKFVAIK) and three short peptides (No 31, AGWRHAGS; No 32,
HKGCAMTA and No 40, GCGNS) (Fig. 6). Of these 16 peptides, one
random-coiled peptide (No 23) had scores beyond 0.9 from both
programs. A recent review had shown that the alpha-helical cationic
anticancer peptides were promising anticancer agents with unique
mechanisms of cytoplasmic membrane disruption leading to necro-
sis and apoptotic induction by interruption of mitochondrial mem-
brane [25]. Alteration of amino acid residues of these predicted
peptides to improve their net charge, hydrophobicity and helicity
could enhance their speciﬁc binding to the cancer cells [8]. Therefore
our ﬁndings could be further optimized by a de novo peptide design
and modiﬁcation.
In discussion, this study examined cytotoxicity of the crude A. fulica
mucus and six HPLC-separated fractions against the breast cancer cell
line MCF-7 by using the MTT assay and found that the F2 and F5 frac-
tions signiﬁcantly induced cell death. These fractions also affected the
normal Vero cells. As the MTT assay measured cell viability by colori-
metric assessing the activity of NADH-dependent oxidoreductase, this
study showed the anticancer activity of the A. fulicamucus and the cyto-
toxic compounds were potentially located in the F2 and F5 fractions. By
scanning eachHPLC-separated fractions at 210–290 nm, the absorbance
at 220 and 280 nmof proteinswas clearly observed. This was supported
by the protein assay and the mass spectrometric analyses of the F2 and
F5 fractions. Therefore, we ascertained that these fractions contained
peptides. Previous study suggested that the snail mucus contained com-
plex mixture of proteoglycans, glycosaminoglycans, glycoproteins,
hyarulonic acid, small peptides and metal ions [26]. As the crude
mucus samples were not processed through enzymatic digestion or
heat treatment, the proteoglycan, glycosaminoglycan and hyarulonicactions of the A. fulicamucus. These two fractions were separated into four sub-fractions:
alyzed by protein assay andmass spectrometry. All sub-fractions were trypsinized except
informatic programs and shown in this ﬁgure. The structures of these peptides were clas-
loop and short peptide. Putative peptides predicted from the F2 fractionwere displayed on
ted the cell-penetrating peptides.
Fig. 7. Amino acid constituents of 16 signiﬁcantly predicted putative anticancer peptides from the F2 and F5 fractions of the A. fulicamucus. Colors represented amino acid properties as
positively-charged, negatively-charged, polar and non-polar.
56 T. E-kobon et al. / Computational and Structural Biotechnology Journal 14 (2016) 49–57acid contents of the mucus could almost be precipitated after centrifu-
gation, yielding only small soluble peptides, glycoproteins and other
small compounds.
The cytotoxic effect of the peptide/protein contents within the F2
and F5 fractions was initially hypothesized as the result of a previously
characterized glycoprotein enzyme of A. fulicamucus, named achacin.
Kanzawa et al. found that the puriﬁed achacin from A. fulica mucus
could induce death of HeLa cells at the IC50 of 10 μg/ml [27]. Achacin
(59 kDa) is an L-amino acid oxidasewhich catalyzes oxidative deamina-
tion of L-amino acids to α-keto acids, hydrogen per oxide (H2O2) and
ammonia (NH3) [28]. The production of H2O2 could induce apoptosis
by causing membrane blebbling. Achacin could also reduce amount of
free amino acids and triggered the caspase pathway causing chromatin
condensation and DNA fragmentation [27,29]. Although an amino acid
sequence of achacin is available in the protein database, proteomic anal-
yses of these two fractions did not detect any peptide fragments of
achacin. Therefore, other small peptides could be the cause of these cy-
totoxic effects.
The peptidomic contents of the F2 and F5 fractions were sub-
fractioned bymolecular sizes before elucidated by themass spectromet-
ric analysis which revealed considerable numbers of small peptides. Lit-
tle information about these various small peptides have been known
because the majority have focused on the large constituents of the
A. fulicamucus. This study predicted approximately 5% of these peptides
were putative anticancer peptides and most of themwere smaller than
10 kDa, considerably tinier than achacin. Further classiﬁcation of these
anticancer peptides after prediction of peptide folding showed ﬁve
structural groups. Bringing together these two parts so that 16 small
cationic amphipathic peptideswith variable structures were ﬁnally pre-
dicted from the F2 and F5 fractions. These peptides were shorter than a
previously reported cysteine-rich antimicrobial peptide (80 amino
acids, 9.7 kDa) from the mucus of A. fulica, named mytimacin-AF [14].
Mytimacin-AF showed antimicrobial activity with the MIC of 1.9 μg/ml
and little hemolytic activity against human red blood cells. Amino acid
sequences of our predicted anticancer peptides did not signiﬁcantly
share similarity with mytimacin-AF. Therefore, this study has identiﬁed
the smallest anticancer peptides from the mucus of A. fulica for the ﬁrst
time. These anticancer peptides could play innate immune protective
roles in the A. fulica. Biochemical synthesis and modiﬁcation of these
peptides are in progress to increase the cytotoxic effect against the
breast cancer cells. Moreover, a single peptide may not solely inhibit
the growth of the MCF-7 cells, combinatorial effects of anticancer pep-
tides and proteins will be further examined.
Several molluscan small bioactive peptides have been previously re-
ported since 1996 inMytilus sp., Crassostrea sp., Ruditapes philippinarum,
Biomphalaria glabrata, Argopecten irradians, Bathymodiolus azoricus,
Chlamis farreri, Haliotis sp., Mercenaria mercenaria, Littorina littorea,
Hyriopsis cumingii, Venerupis philippinarum and A. fulica [30], but onlya few peptides were identiﬁed from gastropod species such as antimi-
crobial peptides in B. glabrata, littorein in L. littorea and Mytimacin-AF
in A. fulica [14]. Most of these peptides were small cationic cysteine-
rich amphipathic molecules. The 16 predicted anticancer peptides in
this study were also small cationic molecules with amphipathic proper-
ties. A proline-rich antimicrobial peptide from the Chilean scallop
A. purpuratus was an example of non-cysteine-rich bioactive peptides
[30]. The anticancer peptides are potential targets over other chemicals
for new therapeutic agents due to their low molecular masses, simple
structures, speciﬁc cytotoxicity to cancer cells over normal cells, various
routes of administration, and lower the risk of drug resistance induction
[31]. These peptides have diverse mechanisms of action as reviewed by
Mulder et al. [31]. The cationic anticancer peptides can bind to the
negatively-chargedmembrane of the cancer cells and disrupt themem-
brane stability and ﬂuidity, such as pore formation by the carpet model
or barrel-stave model, or increase of calcium ion inﬂux, leading to cell
death. Some of these peptides may inhibit cancer cell growth by modi-
ﬁcation of lysosomal membrane, enhancement of proteasome activity,
induction of mitochondrial pathway of apoptosis by the caspase cas-
cade, activation of immune modulatory pathway, and inhibition of
DNA replication-relating genes interfering the cell cycle. Detailed analy-
ses as well as residue modiﬁcation will be conducted for better under-
standing the cytotoxic mechanisms of these 16 peptides. However,
tiny amount of the F2 and F5 fractions as well as their sub-fractions
have been obtained, exhaustive experimental screening of the active
peptides within these fractions are hardly difﬁcult. Synthetic peptides
would be an alternative option for further analysis.
In summary, anticancer property of small peptide contents within
the F2 and F5 HPLC-separated fractions from A. fulica mucus against
the breast cancer cell line MCF-7 was shown. Mass spectrometric and
bioinformatics analyses characterized and predicted relatively small
cationic amphipathic putative anticancer peptide candidates in these
fractions, for the ﬁrst time. These peptides will be promising targets
for new anticancer drug development.
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